LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock Has Consensus Target Price of $110.60 According to Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned an average rating of “Hold” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $110.60.

Several research analysts recently commented on the company. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Wells Fargo & Company lowered their price target on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 5th. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Finally, Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th.

LeMaitre Vascular Trading Up 1.3%

LeMaitre Vascular stock opened at $82.62 on Thursday. The company has a market cap of $1.89 billion, a price-to-earnings ratio of 28.99, a P/E/G ratio of 2.35 and a beta of 0.48. The firm has a 50-day moving average of $80.87 and a 200-day moving average of $94.46. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. LeMaitre Vascular has a one year low of $78.22 and a one year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). The company had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. LeMaitre Vascular’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 EPS. On average, equities analysts expect that LeMaitre Vascular will post 2.89 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Thursday, August 20th were issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date was Thursday, August 20th. LeMaitre Vascular’s payout ratio is presently 35.09%.

Institutional Trading of LeMaitre Vascular

Several institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. BlackRock Inc. acquired a new stake in LeMaitre Vascular in the second quarter valued at $314,075,000. Conestoga Capital Advisors LLC grew its position in shares of LeMaitre Vascular by 3.6% in the 1st quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock valued at $161,224,000 after acquiring an additional 51,825 shares during the period. First Trust Advisors LP grew its position in shares of LeMaitre Vascular by 6.2% in the 1st quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock valued at $108,959,000 after acquiring an additional 57,931 shares during the period. Copeland Capital Management LLC increased its stake in shares of LeMaitre Vascular by 10.1% during the 3rd quarter. Copeland Capital Management LLC now owns 924,081 shares of the medical instruments supplier’s stock worth $76,320,000 after purchasing an additional 84,618 shares during the last quarter. Finally, Ranger Investment Management L.P. acquired a new position in shares of LeMaitre Vascular during the 2nd quarter worth about $21,045,000. 84.64% of the stock is owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a medical device company that develops, manufactures and markets products used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on blood vessels outside the heart and brain, including procedures involving the carotid, lower-extremity and aortic vascular systems.

The company’s product portfolio includes biologic and synthetic vascular grafts, angioplasty and thrombectomy catheters, valvulotomes, carotid shunts, vascular clamps and other devices used in open and minimally invasive vascular surgery.